What's Hot

View all perspectives
      Ab#1582 @RheumNow #ACR23
      RA-ILD outcomes of TNFi v non-TNF b/tsDMARD
      VA Data, propens match emulation study
      No incr ris

      Eric Dein

      1 year ago
      Ab#1582 @RheumNow #ACR23 RA-ILD outcomes of TNFi v non-TNF b/tsDMARD VA Data, propens match emulation study No incr risk of death in TNFi vs non-TNFi But are TNF safe? - Don't support systematic avoidance. But are there specific pops - unsure. Don't answer if efficacy in RA-ILD https://t.co/AApEjZs4DM
      Important plenary session, RA-ILD outcomes in VA cohort study

      No difference in death/hospitalization for TNF vs non-TNF

      Mike Putman EBRheum

      1 year ago
      Important plenary session, RA-ILD outcomes in VA cohort study No difference in death/hospitalization for TNF vs non-TNF treated patients. Jives w/my priors; I do NOT avoid TNF in RA-ILD Encouraging if you (like me) prefer RA-active tx for RA-ILD 😉😆 @RheumNow #ACR23 #ACRBest https://t.co/TIDzMLOfs4
      World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK invol

      Dr. Rachel Tate

      1 year ago
      World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK involvement vs ljSSc pts w/ more cardiac involvement. No significant differences in ILD, PAH, GI involvement. #ACR23 Abs #1623 https://t.co/czAH0hpY2a @rheumnow https://t.co/RcfAJORXY3
      Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-relat

      Richard Conway

      1 year ago
      Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU
      The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need

      sheila

      1 year ago
      The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX Reassuring. . . . In my practice, pts tolerate MTX split dosing better esp w/⬆️doses #ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4
      #ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical fo

      Dr. Rachel Tate

      1 year ago
      #ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical for understanding mechanisms of health disparity, targeting interventions and, ultimately, improving quality of care. https://t.co/Fd2m4yzlHp @rheumnow https://t.co/EhIIF9cquQ
      RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by Rheu

      Dr. John Cush RheumNow

      1 year ago
      RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
      Long term follow up T2T in RA

      12 yrs BeST & 20yrs IMPROVED studies

      50% recalled
      68% remission 91% LDA
      HAQ 0.5

      Th

      Aurelie Najm

      1 year ago
      Long term follow up T2T in RA 12 yrs BeST & 20yrs IMPROVED studies 50% recalled 68% remission 91% LDA HAQ 0.5 These are GOOD outcomes Especially considering setup before we had several MoAs What’s lacking: current ttmt & number of bioD, ctrl group @RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc
      #ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use

      Md Yuzaiful Md Yusof

      1 year ago
      #ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN
      Does NSAID use = CKD?
      Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbi

      Robert B Chao, MD

      1 year ago
      Does NSAID use = CKD? Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities. Long term NSAID use not associated with increased risk of CKD. @RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc
      OA and Microbiome!
      Ab#1581 @RheumNow #ACR23
      Microbiome transplantation of mouse models - benefit if before or soon afte

      Eric Dein

      1 year ago
      OA and Microbiome! Ab#1581 @RheumNow #ACR23 Microbiome transplantation of mouse models - benefit if before or soon after OA induction (meniscal destabilization) ⭐️OA is inflammatory dis of innate immune sys, not "wear-and-tear" and gut biome may be a 🔑 https://t.co/eA8unUBnpC
      Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @r

      Dr. Rachel Tate

      1 year ago
      Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX
      Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity.
      Importance of supporting p

      Robert B Chao, MD

      1 year ago
      Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity. Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise! @RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0
      Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse level

      Robert B Chao, MD

      1 year ago
      Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline! Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases @RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG
      RA-ILD is an heterogeneous condition

      Different risk factors identified dep/ on radiographic pattern

      RA-UIP:

      -male sex

      Aurelie Najm

      1 year ago
      RA-ILD is an heterogeneous condition Different risk factors identified dep/ on radiographic pattern RA-UIP: -male sex OR 2.7 -ACPA+ OR 2.2 -male + ACPA + smoking OR 13 RA-NSIP: -RF+ OR 3.2 Likely to support different pathological mechanisms @RheumNow #ACR23 ABST1269 https://t.co/rC2F9YAceQ

      Podcasts

      • ACR24 SpA Topic Panel Key Discussions on Spondyloarthritis
      • ACR24 - RHEUMATOID ARTHRITIS
      • ACR24 - IL - 17

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.